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Introduction
Pancreatic Cystic Neoplasms (PCNs) are potential precur-
sors of pancreatic cancer.1 With the widespread use of radio-
logic cross-sectional imaging, PCNs are discovered with 
increasing frequency. The prevalence of pancreatic cysts in 
patients undergoing cross-sectional imaging of the abdomen 
is estimated to be ~2.4%.2 Patients with a PCN have been 
shown to have a 35 times higher age- and gender-adjusted 
incidence of pancreatic malignancy compared with a noncyst 
population.1 Therefore, PCNs are generally regarded as pre-
malignant lesions and preemptive resections are often con-
sidered necessary.
Surgical treatment of cysts varies from pancreaticoduo-
denectomy to distal pancreatectomy with or without sple-
nectomy. These invasive procedures are associated with 
a significant risk of morbidity and mortality, which may be 
unnecessary when the cyst has little to no malignant potential. 
In the past, some studies showed that half of the pancreatic 
cysts resected turned out histopathologically to be a pseudo-
cyst, while the remainder consisted of true PCNs of various 
origins and dysplastic grade.3 In recent years, diagnostic per-
formance has improved considerably, but nevertheless there 
is need for better identification of cysts with malignant poten-
tial. Studies validating the initial criteria for resection of PCN 
(i.e., Sendai guidelines4) have shown a high sensitivity, close 
to 100%, but very low specificity of 25–30%.5 The revised 
guidelines released in 2012 (Fukuoka guidelines6) appear to 
perform better,7 but nevertheless, have shown that 67.7% of 
resected patients are still exposed to unnecessary surgery 
for cysts which in hindsight were low risk PCN.8 Thus, there 
is an urgent need for additional predictors to aid in the clinical 
decision making whether to operate or not.
Endoscopic ultrasound (EUS) is considered a valuable 
asset to aid in the differentiation between various pancre-
atic cysts including intraductal papillary mucinous neoplasm 
(IPMN) and mucinous cystic neoplasms, however, it unfortu-
nately does not allow reliable identification of the presence 
and/or risk of malignant transformation other than the iden-
tification of nonspecific morphological features like mural 
nodules or asymmetric cyst wall thickening. Unfortunately, 
there is a poor correlation between morphological features 
and dysplastic grade. Biomarkers such as carcinoembryonic 
antigen, while able to help distinguish between mucinous and 
nonmucinous cysts, have shown limited sensitivity and spec-
ificity for diagnosis and prognosis of pancreatic cancer.9–12 
Several other markers have been investigated, including 
carbohydrate antigen 19-9, although, again, poor sensitivity 
and specificity preclude the use of this marker for pancreatic 
cancer diagnosis.13
Currently, there is an increasing interest in the potential 
use of pancreatic cyst fluid in the treatment algorithm of 
patients with pancreatic cysts. Cyst fluid obtained by EUS-
fine needle aspiration (EUS-FNA) may contain precancer-
ous cells which potentially can be identified by mutational 
status analysis. KRAS mutations are common in pancreatic 
cancer and the largest study to date investigating the use 
of KRAS mutation detection in pancreatic cyst fluids was 
the pancreatic cyst DNA analysis (PANDA) study.14 They 
showed that while KRAS mutations were more prevalent 











Official journal of the American Society of Gene & Cell Therapy
Validation of a 9-microRNA Panel in Pancreatic Cysts
Utomo et al.
A subset of pancreatic cystic neoplasms are regarded as precursor lesions of pancreatic cancer, but only a minority of all 
pancreatic cystic neoplasms will undergo malignant transformation. MicroRNAs are increasingly recognized as molecular 
targets in carcinogenesis. Previously, a 9-microRNA (miR) signature was suggested to discriminate between high risk and 
low risk pancreatic cystic neoplasm. In this study, we aimed to validate this 9-miR panel in a prospective cohort. Total miR 
was isolated from pancreatic cyst fluid and expression of miR18a, miR24, miR30a-3p, miR92a, miR99b, miR106b, miR142-3p, 
miR342-3p, and miR532-3p was analyzed by singleplex Taqman MicroRNA Assay. A total of 62 patient samples were analyzed. 
During follow-up, 24 (38.7%) patients underwent resection, of which 6 (9.7%) patients showed at least high grade dysplasia. 
A logistic regression model presented a “predicted risk” score which significantly differed between low and high risk cysts, 
either including all patients or only those with histological confirmation of diagnosis. Using a set cut-off of 50%, the sensitivity 
of the model for the total cohort was 10.0%, specificity 100.0%, positive predicted value 100.0%, negative predicted value 85.2%, 
and diagnostic accuracy of 85.5%. Thus, while observing a significant difference between low and high risk cysts, clinical 
implementation of this biomarker panel is as yet unlikely to be beneficial in the management of pancreatic cysts.
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in mucinous cysts, the presence of KRAS mutations did 
not distinguish premalignant from malignant cysts, and 
while additional allelic loss was highly specific for malig-
nant cysts (96%), sensitivity was low (37%). However, next 
generation sequencing may improve sensitivity, and com-
bining molecular markers (i.e., BRAF, CDKN2A, CTNNB1, 
GNAS, KRAS, NRAS, PIK3CA, RNF43, SMAD4, TP53, and 
VHL and loss of heterozygosity thereof) together with clini-
cal markers may improve diagnostic accuracy of PCN.15–17
Biomolecules released by dysplastic cells may also be 
present in cyst fluid, and may aid in the identification of prema-
lignant cysts. One such potential biomarker is the presence 
of miRs in pancreatic cyst fluid, which could be differentially 
expressed in benign, dysplastic, and malignant cysts.
MicroRNAs (MiRs) are small, noncoding, functional 
RNAs of ~21–23 nucleotides in length that are involved in 
epigenetic regulation by binding to specific mRNAs, leading 
to their degradation and translational repression.18 It has 
been shown that expression levels of miRs differ between 
various pathological conditions, including cancer.19 Fur-
thermore, miRs can be quantified in several types of bodily 
fluid20 and are extremely stable, showing resistance against 
endogenous RNase activity.21 In 2012, Matthaei et al. pub-
lished a 9-miR model, which showed that a panel of nine 
miRs measured in pancreatic cyst fluid were able to dif-
ferentiate between low risk cysts and high risk cysts, which 
allowed stratification of patients into those eligible for either 
surgery or watchful waiting with a sensitivity of 89%, speci-
ficity of 100%, and area under the curve of 1.22 However, 
clinical implementation of these promising results requires 
validation. Hence, in this study, we aimed to prospectively 




In total, 92 pancreatic cyst fluid samples were collected dur-
ing the study period. Of those, 12 samples were excluded 
due to technical difficulties during isolation or inconclusive 
diagnosis. Samples were spiked with a known concentra-
tion of the nonhuman miRNA cel-miR39 in order to confirm 
efficient isolation of miRs from the sample. In three cases, 
levels of cel-miR39 after isolation were too low (Ct >30) to 
assure efficient miR isolation, and samples were discarded 
(see Supplementary Figure S1).  Finally, unreliable mea-
surement of one of the miRs in the panel occurred in 15 
samples. Final analysis was performed in 62 patients — 
see Figure 1 for the flowchart of the study and Table 1 
for the clinical patient characteristics. In total, 52 patients 
with a low risk cyst were included, versus 10 patients with 
a high risk cyst. Histological confirmation of diagnosis was 
available through EUS-FNA for 11 patients (17.8%) and 
by histology after surgery for 24 (38.7%) of which, 25% (6 
out of 24) had high grade dysplasia or invasive carcinoma. 
The remainder of the patients (27; 43.5%) was followed up 
for a mean duration of 26.59 (0–74.25) months, and for all 
patients diagnosis known at the end of the follow-up was 
used.
Figure 1  Flowchart of the study population.
EUS-FNA obtained cyst fluid (n = 92)
Excluded due to
inconclusive diagnosis,
duplicates in time, or
technical isolation
problems (n = 12)
Cyst fluid for microRNA isolation and 
measurement (n = 80)
low risk cyst = 70; high risk cysts = 10
Samples for initial analysis (n = 76)
low risk cyst = 66; high risk cysts = 10
Samples for final analysis (n = 62)
low risk cyst = 52; high risk cysts = 10
Excluded due to low
isolation effciency (spiked
cel-miR-39>Ct 30; n = 4)
Excluded due to unreliable
measurement of one or
more microRNAs (n = 15)




cyst (n = 52)
High risk 
PCN (n = 10)
Age, years
  Range 19.9–79.5 19.9–79.5 45.5–78.4
  Mean (SD) 59.6 (13.4) 58.5 (13.7) 65.5 (10.6)
Gender, n (%)
  Male 20 (32.3) 14 (26.9) 6 (60.0)
  Female 42 (67.7) 38 (73.1) 4 (40.0)
Diagnosis, n (%)
  Main Branch IPMN 3 (4.8) 1 (1.9) 2 (20.0)
  Side Branch IPMN 18 (29.0) 16 (30.8) 2 (20.0)
  Mixed Type IPMN 4 (6.5) 0 (0) 4 (40.0)
  Mucinous Cystic Neoplasm 13 (21.0) 11 (21.2) 2 (20.0)
  Serous Cystadenoma 15 (24.2) 15 (28.8) 0 (0)
  Pseudocyst 9 (14.5) 9 (17.3) 0 (0)
Histological confirmation, n (%)
  None 27 (43.5) 23 (44.2) 4 (40.0)
  EUS-FNA 11 (17.8) 11 (21.2) 0 (0)
  Surgery 24 (38.7) 18 (34.6) 6 (60.0)
Dysplasia, of resected (n = 24)
  No dysplasia 6 (25.0)
  Low grade dysplasia 9 (37.5)
  Moderate grade dysplasia 3 (12.5)
  High grade dysplasia 5 (20.8)
  Invasive carcinoma 1 (4.2)
PCN, pancreatic cystic neoplasms; EUS-FNA, endoscopic ultrasound-fine 
needle aspiration; IPMN, intraductal papillary mucinous neoplasm.
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Individual miRs and calculated diffpairs show no 
significant difference between low risk cysts and high 
risk cysts
In total, nine miRNA expression levels were measured. Com-
paring the total expression of these individual miRs did not 
show significant differences in mean Ct values between low 
risk and high risk cysts (Figure 2). MiR expression levels were 
subsequently normalized by making seven distinct “diffpairs” 
(i.e., seven combinations of two miRNAs), where values 
were generated by comparing the expression levels of the 
two miRNAs in that diffpair. The choice of miRNA pairing was 
based on earlier results by Matthaei et al., who defined these 
diffpairs based on the most differentially expressed diffpairs 
used in a L1-penalized logistic regression model (miR18 was 
combined with miR92a, miR24 with miR30a-3p, miR30a-3p 
with miR532-3p, miR24 with miR99b, miR106b with miR92a, 
miR142-3p with miR92a, and miR24 with miR342-3p). One of 
these diffpair combination (diffpair (miR106b;miR92a)) was 
found to be significantly different between low risk cysts and 
high risk cysts (Figure 3). This difference did not hold up in 
the logistic regression and was therefore considered not clini-
cally relevant. Of note, generating other diffpairs also did not 
result in significant differences in diffpairs observed between 
high risk and low risk cysts (see Supplementary Table S1).
The logistic regression model using diffpairs is 
significantly different between low risk cysts and high 
risk cysts
The diffpairs were entered in a logistic regression model using 
previously published regression coefficients.22 The regression 
coefficient represents the weight given to each diffpair in the 
model, i.e., in this weighted model each diffpair does not con-
tribute equally to the equation. Diffpair (miR24;miR30a-3p) 
and diffpair (miR18a;miR92a) contributed the most in this 
model (see Supplementary Table S2). Exploring the possi-
bility for recalibration did not lead to improved discrimination 
between low risk and high risk cysts (data not shown). The 
diffpairs in the logistic regression model together generate 
a risk score (named the “predicted risk” (13)) which ranges 
from 0% and 100%. The mean predicted risk was 13.97% for 
low risk cysts versus 27.3% in the high risk cysts  (Figure 4; 
P = 0.013). Comparing high risk IPMN to either low risk 
IPMN alone or low risk mucinous cystic neoplasms alone 
also showed significant higher predicted risk in the high risk 
IPMN (P = 0.0286 and 0.0093, respectively; Supplemen-
tary  Figure S2). The diagnostic performance of the logistic 
regression model classified as fair in separating low risk cysts 
from high risk cysts, with an area under the receiver operator 
curve of 0.75 (Figure 5a). Excluding all cases without a histo-
logical confirmation, the diagnostic performance increased to 
good discrimination with an area under the receiver operator 
charecteristic curve of 0.83  (Figure 5b). These data demon-
strate that the 9-miR panel shows potential for distinguishing 
high risk and low risk cysts.
The established cut-off value of 50% is not clinically 
implementable
Reliable implementation of a diagnostic tool requires reliable 
cut-off levels with sufficient sensitivity and specificity. From 
the coordinates of the receiver operator charecteristic curve, 
we explored various cut-off values and evaluated diagnostic 
Figure 2 The mean expression of individual microRNAs of the 
9-microRNA panel. There were no significant differences in the 
expression of the microRNAs between low risk cysts and high risk 

















































Figure 3 Graph depicting the diffpair expression between low 
risk cysts and high risk cysts. Diffpair (106b; 92a) was significantly 
different (P = 0.028) between low risk and high risk cysts, however, 
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characteristics of each of these cut-off points (Table 2). First 
we employed a cut-off value of 50%, as this was the value 
suggested in the study of Matthaei et al.22 In our study, a 
cut-off of 50% yielded a sensitivity of 10.0%, specificity of 
100.0%, positive predicted value of 100.0%, negative pre-
dicted value of 85.5%, and diagnostic accuracy of 85.5%, 
which was significantly poorer than the previously reported 
results. In our study, the optimal cut-off value was 25.66%, 
as determined by the sensitivity and specificity curve using 
Graphpad Prism 5 (version 5.01) (Figure 6a), and confirmed 
using an online cut-off calculator tool. The diagnostic charac-
teristics of the optimal cut-off were 60.0% sensitivity, 90.4% 
specificity, 54.5% positive predicted value, 92.2% negative 
predicted value, and 85.5% diagnostic accuracy (Table 2). 
Only taking samples with the golden standard into account 
yielded an optimal cut-off value of 25.0% (Figure 6b) which 
results in a sensitivity of 66.7%, specificity of 89.7%, positive 
predicted value 57.1%, negative predicted value 92.9%, and 
diagnostic accuracy of 85.7% (Table 3).
Discussion
With the growing detection of pancreatic cysts of various 
sizes, it is becoming increasingly important to discriminate 
between harmless cystic lesions and cysts that have high 
malignant potential. We prospectively validated a promising 
9-miR panel as biomarker for the detection of high risk cysts 
which should be resected based on the dysplastic transfor-
mation within the epithelial lining.22 While in our study we 
observed a significant difference between low risk cysts and 
high risk cysts in the predicted risk of the 9-miR model, the 
threshold of 50% as proposed by Matthaei et al. does not 
unequivocally segregate low risk from high risk cysts and is 
accompanied by a very low sensitivity of 10%.
Recently published guidelines of the American Gastroen-
terological Association regarding asymptomatic cysts have 
led to a major debate regarding the implementation of these 
guidelines.23–26 Nine out of ten recommendations for surgery 
were deemed to be based on very low quality evidence,23 
underlining the necessity for a more objective measurement 
in patients with this increasingly frequent lesion. The impor-
tance of finding and validating novel biomarkers for identifi-
cation of high risk cysts is further emphasized by the high 
rate of resections performed for low risk PCN (specifically in 
mucinous cystic neoplasms and side branch-IPMN).8
Figure 4 Graph depicting the predicted probability for 
resection. The predicted probability is significantly higher in the high 
risk cyst group (P = 0.013). In the paper published by Matthaei et al., 
a threshold of 50% (dotted line) was used to determine the need for 






















Figure 5 Receiver operator characteristic (ROC) curve of the logistic regression model in predicting cysts that require resection. (a) ROC of 
the whole cohort. (b) ROC excluding samples without histologic confirmation.
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MiRs are being widely investigated as a biomarker for 
the early detection, diagnosis, prognosis, and treatment 
response of numerous cancers. The field is rapidly evolv-
ing and the first phase 1 trial using a miRNA mimic in liver 
cancer is currently ongoing.27 As a biomarker, they hold sev-
eral advantages — e.g., they are very stable and thus mea-
surable across different tissues and different moments in 
time. Furthermore, miR signatures have been shown to be 
specifically associated with various types of cancer.28 Most 
importantly, it is assumed that distinct miRs are released by 
tumor cells into their environment, and make their way to the 
periphery, thereby making it possible to measure them in for 
example blood samples and reducing the need for invasive 
procedures. The downside to this approach is that circulating 
miR levels can be sensitive to subtle changes in the human 
body, including diet and viral infections, leading to conflict-
ing results.29,30 Moreover, the optimal compartment of blood 
(whole blood, serum, or plasma) in which miRNAs should be 
measured is still matter of discussion.31
A multitude of circulating miRs has been associated with 
the detection of pancreatic ductal adenocarcinoma.32–34 
These studies, however, generally show considerable dis-
similarities in reported miRNAs.35 The use of serum miRs for 
pancreatic lesion distinction has been described, albeit in a 
low number of cases, and could be hampered by the fact 
that the cyst is a closed compartment.36 This may impede 
the dispersion of molecular markers in the circulation. Using 
pancreatic cyst fluid as the source for miR measurements 
may overcome this problem. Several studies have indicated 
that the use of miRs as a biomarker for malignant degenera-
tion of pancreatic cysts may show promise.22,37,38 However, 
similar to the problems in circulating miRs, there is no con-
sensus in the best endogenous control for the normalization 
in pancreatic cyst fluid. Two of these studies have chosen the 
small nucleolar RNA, RNU6B, as their endogenous control. 
However, the use of RNU6B for expression normalization has 
been reported to result in bias and erroneous findings, as 
they are not stably expressed in all tissues and fluids.39–42 The 
study by Matthaei et al. was unique by a different approach 
of normalization using diffpairs which was described earlier 
in ref. 43.
The 9-miR model as described by Matthaei et al. was 
derived from high throughput analysis of 11 cyst fluid sam-
ples and subsequently validated using singleplex quantitative 
reverse transcription-polymerase chain reaction (PCR) in 37 
cyst fluid samples. In the validation cohort a threshold of 50% 
yielded a sensitivity of 89% and specificity of 100%.22 In our 
study, we performed an external validation of the use of this 
model and observe a significant difference in predicted risk 
of low risk and high risk cysts. Despite this difference, the 
proposed cut-off value of 50% yielded a sensitivity of only 
10% and specificity of 100.0%. While our study showed a 
diagnostic accuracy of 85.5%, we feel this may be biased by 
the low numbers of high risk cysts in our cohort. In addition, 
with the sensitivity differing so much between these stud-
ies, further validation in other cohorts is warranted before 
any clinical implementation may be considered. Employing 
various other cut-off values improved diagnostic accuracy to 
levels that are theoretically suitable for clinical implementa-
tion, however, this is most likely due to overfitting of our study 
population and lacks generalizability. Even though miRs have 
been studied for a couple of decades in particular for applica-
tion in the field of cancer, only few have made it into clinical 
trials, and even less are being used in the clinic despite ini-
tial promising results.44 For a biomarker to be implemented in 
routine clinical care, reproducibility across different hospitals 
or laboratories must be shown, making this study important 
for the validation of the 9-miR model in pancreatic cyst fluid.45
This study has several limitations. First, as pancreatic cyst 
fluid is only collected from a lesion requiring a EUS-FNA, 
Table 2 Diagnostic characteristics of the logistic regression model
Cut-off, % Sensitivity, % Specificity, % Positive predictive value, % Negative predictive value, % Diagnostic accuracy, %
8 90.0 28.8 19.6 93.8 38.7
10 90.0 42.3 23.1 95.7 50.0
25 50.0 88.5 50.0 92.0 83.9
25.66 60.0 90.4 54.5 92.2 85.5
50 10.0 100.0 100.0 85.2 85.5
Cut-off value in bold marks the calculated optimal threshold.
Figure 6 Calculation of the optimal threshold value. Calculation 
of the optimal threshold value as derived from (a) the whole cohort 
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the study group suffers from a selection bias. However, we 
believe that this is exactly the population that is most likely to 
benefit from a molecular marker considering the poor diag-
nostic yield of cytology in itself.9 Second, validation of dis-
ease by the golden standard of histology was not performed 
in all patients in our cohort. This is potentially problematic, as 
the current guidelines are not 100% accurate in predicting 
malignancy. However, we have previously shown that clas-
sification of PCN was >95% accurate in our tertiary referral 
center. Furthermore, excluding patients without histological 
confirmation, while improving the sensitivity slightly, still did 
not result in the clear discrimination as reported by Matthaei 
et al. Third, patients with a small cyst which cannot be reached 
with an EUS-FNA will not benefit from a biomarker based on 
cyst fluid, however this holds true for most biomarker studies 
in pancreatic cyst fluid unless the use of secretin is consid-
ered.46 Prospective studies to follow the natural development 
of these small asymptomatic lesions are needed.
MiRs can be rapidly and efficiently isolated from pancre-
atic cyst fluid, making them ideal biomarkers for monitoring 
dysplastic changes within the cyst. However, in our study, we 
were unable to replicate the diagnostic characteristics of a 
promising 9-miR model in pancreatic cyst fluid. More stud-
ies are needed to find the holy biomarker grail in pancreatic 
cyst fluid, whether it be DNA-based, (micro)RNA-based, or 
protein-based.
Conclusions
With cystic lesions ever more frequently found in the pan-
creas, there is a pressing need for an objective marker to 
aid the management of pancreatic cysts. Here, we validated 
a 9-miR panel that has shown great promise in the discrimi-
nation between low and high risk cysts. In our study, while 
observing a significant difference between the two groups, 
the diagnostic characteristics corresponding to various cut-
off values were poor. Thus, the clinical implementation of this 
biomarker panel is as yet unlikely to be beneficial in the man-
agement of pancreatic cysts.
Materials and methods
Pancreatic cyst fluid acquirement. From January 2009 to 
October 2013 all patients analyzed for a pancreatic cyst, 
who subsequently underwent EUS-FNA were included. This 
study received approval of the Institutional Review Board 
(MEC-2008–233 and MEC-2012–107). A declaration of Hel-
sinki protocols was followed and all patients provided written 
informed consent. The pancreatic cyst fluid was stored sterile 
at −80°C until analysis.
The primary objective of the study was the validation of the 
9-miR panel for the prediction of a low risk or high risk cyst. 
Low risk cysts consist of cystic lesions without dysplasia, 
low grade dysplasia and moderate grade dysplasia of which 
follow-up is indicated. Low risk cysts were defined as no dys-
plasia, low grade dysplasia or moderate dysplasia. High risk 
cysts were defined as cystic lesions with high grade dyspla-
sia or invasive carcinoma, which should be resected. The risk 
classification of PCN occurred based on histopathology, or 
updated Sendai guidelines when histopathological data was 
unavailable.
Total MiR isolation. Total miR was isolated from pancreatic 
cyst fluid using the Taqman miRNA ABC Purification Kit–
Human Panel A (Applied Biosystems, Glasgow, UK), accord-
ing to the manufacturer’s protocol. In short, lysates were 
prepared from pancreatic cyst fluid and subsequently trans-
ferred to tubes containing anti-miRNA Dynabeads. These are 
superparamagnetic beads bound to a set of 377 anti-miRNA 
oligonucleotides. As a positive control and measure for iso-
lation efficiency, the samples were spiked with 1 nmol/l of 
nonhuman cel-miR-39 prior to isolation. After hybridization, 
the beads were washed and the miRs were eluted in 100 µl 
elution buffer from aforementioned purification kit.
cDNA synthesis. Taqman MicroRNA Reverse Transcription 
Kit (Applied Biosystems) was used to convert the selected 
miRs into cDNA according to the manufacturer’s protocol. 
A total volume of 15 µl (11.25 µl miRNA RT mix + 3.75 µl 
miRNA sample) was used for the RT reaction. Samples were 
incubated at 16°C for 30 minutes, 42°C for 30 minutes, 85°C 
for 5 minutes, and kept at 4°C using the StepOnePlus Real-
Time PCR System (Life Technologies, Carlsbad, CA).
MiR expression analysis by quantitative reverse transcriptase-
PCR. The reverse transcription (RT) product from the cDNA 
synthesis step was used in a singleplex Taqman MicroRNA 
Assay reaction according to the manufacturer’s protocol. In 
short, 18 µl of the Taqman PCR mix was mixed with 2 µl of 
the RT reaction solution obtained from the RT step. The PCR 
was run at 95°C for 10 minutes, 95°C for 15 seconds, and 
60°C for 60 seconds for 40 cycles using the StepOnePlus 
Real-Time PCR System (Life Technologies). MiR expression 
levels were measured in duplicate.
Selected miRs. We measured the expression levels of 
miR18a, miR24, miR30a-3p, miR92a, miR99b, miR106b, 
miR142-3p, miR342-3p, and miR532-3p as previously 
reported.22
Statistical analysis
Exclusion. Samples were excluded when the diagnosis was 
inconclusive, or when there were technical problems with 
the miR isolation procedure such as clumping of beads. 
Table 3 Diagnostic characteristics of the logistic regression model in patients with histological confirmation only
Cut-off, % Sensitivity, % Specificity, % Positive predictive value, % Negative predictive value, % Diagnostic accuracy, %
8 100.0 41.4 26.1 100.0 51.4
10 100.0 55.2 31.6 100.0 62.9
25 66.7 89.7 57.1 92.9 85.7
50 16.7 100.0 100.0 85.3 85.7
Cut-off value in bold marks the calculated optimal threshold.
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Furthermore, samples that showed cel-miR39 expression of 
Ct values above 30 were excluded, as these present samples 
in which the RNA isolation was inefficient. Of the remain-
ing samples, individual quantitative PCR measurements of 
miRNAs were excluded when duplicates showed large devi-
ations. Large deviations of duplicates were defined as dupli-
cates that differed >1.96 times the SD of the miR measured 
in the whole cohort. When both Ct values were >35, deviation 
correction was not applied due to the imprecision in detection 
of such low concentrations of the miR.
Diffpairs, risk score, and logistic regression. The generation 
of diffpairs was performed for normalization of the pancre-
atic cyst fluid as described elsewhere.43 The nine individual 
miRNAs measured were combined into seven pairs, the so 
called ‘“diffpairs”, as defined by Matthei et al. Diffpair values 
were generated by subtracting normalized Ct values of the 
two miRs in that pair (e.g., diffpair (miR18;miR92a) was gen-
erated by subtracting Ct(miR18) – Ct(miR92a)). The values 
obtained from these diffpairs were used to generate a risk 
score based on published regression coefficients, and sub-
sequently entered in a logistic regression model to gener-
ate a score between 0 and 100%.22 Differences between the 
scores of low risk cysts and high risk cysts were tested by the 
Mann-Whitney U-test. A P-value of < 0.05 was considered 
statistically significant. The diagnostic performance of high 
risk cysts of this model was analyzed with a receiver operator 
characteristic curve. Sensitivity, specificity, positive predic-
tive value, negative predictive value, and diagnostic accuracy 
were calculated using various cut-off values of the model. 
The optimal cut-off value was determined using a sensitivity 
and specificity curve, and confirmed using the freely avail-
able online tool “Cutoff Finder”.47
Supplementary material
Figure S1. Ct values of spiked C. elegans miR-39. Samples 
that showed cel-miR39 expression of Ct values above 30 
were excluded, as these present samples in which the RNA 
isolation was inefficient.
Figure S2. Graph depicting the predicted probability for re-
section.
Table S1. Table showing the p-value of a Mann-Whitney U 
test comparing all possible diffpair combinations between low 
and high risk cysts.
Table S2. Regression coefficients used in the logistic regres-
sion model, adapted from Mattaei et al.
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